FLT3 and acute myeloid leukemia: Considering these results, we postulate several clinical consequences: (1) the FLT3-ITD subgroup analysis should be implemented in diagnostic algorithms at diagnosis; (2) midostaurin maintenance therapy needs to be evaluated critically in case of FLT3-ITD located within the TKD1 domain; and (3) when lacking reliable MRD markers in AML patients with a prognostically relevant FLT3-ITD subtype, alloHSCT should be considered in first CR.